TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announced that a leading cell and gene therapy (CGT) manufacturer has selected its SteraMist ionized hydrogen peroxide (iHP) technology for a commercial‑scale facility. The announcement, made on December 22 2025, signals a significant contract win in a high‑growth sector that is projected to reach $51.15 billion in the United States by 2034.
The implementation will deploy multiple SteraMist systems for surface treatment and automated room fogging, and will include TOMI’s standard operating procedure development and installation and operational qualification performed by its Qualification Team. The CGT client will also receive whole‑facility fogging services from TOMI’s iHP Corporate Service team, covering manufacturing suites, quality control laboratories and support spaces to maintain a sterile environment that meets current Good Manufacturing Practices (cGMP) requirements.
The deal underscores TOMI’s strategy to expand its footprint in the life‑sciences market, where demand for validated, scalable decontamination solutions is accelerating as manufacturers shift from development to commercial production. While the contract value was not disclosed, the win adds to a series of recent agreements, including a $500,000 purchase order announced on December 18 2025 and a $3 million custom‑integration pipeline that the company has been building.
James Cherrey, TOMI’s Director of Product Compliance and Manufacturing, said the collaboration demonstrates the company’s ability to support CGT manufacturers as they scale. “As CGT manufacturers transition from development to commercial‑scale production, the need for validated, scalable contamination‑control solutions grows,” he said. “This multi‑stage implementation shows our ability to deliver a turnkey approach that aligns with cGMP requirements and long‑term operational needs.”
TOMI’s recent financial results show a 66 % year‑over‑year decline in revenue to $1.03 million for the quarter ended June 30 2025, and a net loss of $0.06 per share. The company’s gross margin improved to 66 % from 62 % in the prior year quarter, reflecting cost discipline amid a challenging revenue environment. The new CGT contract, while not immediately reflected in quarterly earnings, is expected to contribute to revenue growth and service‑based revenue as the company expands its commercial‑scale deployment capabilities.
The company has also filed a $50 million universal shelf registration and secured an equity line of credit, positioning it to fund future growth initiatives. Analysts note that the CGT market’s rapid expansion presents a tailwind for TOMI, but investors remain focused on the company’s ability to translate contract wins into sustained revenue and profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.